

Wiesław Jerzy Cubaś

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/642917/publications.pdf>

Version: 2024-02-01

108
papers

2,318
citations

361045

20
h-index

253896

43
g-index

111
all docs

111
docs citations

111
times ranked

3306
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?. <i>Journal of Sleep Research</i> , 2022, 31, e13400. | 1.7 | 11 |
| 2 | Perspectives for therapy of treatment-resistant depression. <i>British Journal of Pharmacology</i> , 2022, 179, 4181-4200. | 2.7 | 30 |
| 3 | The Brain-Skin Axis in Psoriasis Psychological, Psychiatric, Hormonal, and Dermatological Aspects. <i>International Journal of Molecular Sciences</i> , 2022, 23, 669. | 1.8 | 34 |
| 4 | Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. <i>Cells</i> , 2022, 11, 645. | 1.8 | 8 |
| 5 | An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86. | 1.7 | 107 |
| 6 | Commentary concerning treatment of depression in patients with heart failure according to 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 2140-2141. | 0.8 | 2 |
| 7 | Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15. | 1.3 | 38 |
| 8 | Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110110. | 1.2 | 2 |
| 9 | Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression. <i>Medicina (Lithuania)</i> , 2021, 57, 274. | 0.8 | 6 |
| 10 | Magnesium in Ketamine Administration in Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2021, 14, 430. | 1.7 | 1 |
| 11 | Gut Microbiota in Depression: A Focus on Ketamine. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 693362. | 1.0 | 15 |
| 12 | Ketogenic diet for depression: A potential dietary regimen to maintain euthymia?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110257. | 2.5 | 23 |
| 13 | Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. <i>Medicine (United States)</i> , 2021, 100, e26769. | 0.4 | 10 |
| 14 | Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2637-2646. | 1.0 | 19 |
| 15 | Screening and diagnosis for mood and anxiety disorders in epilepsy: Polish population reference values. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 351-356. | 0.6 | 4 |
| 16 | Commentary on: Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness, and neurocognitive performance in healthy volunteers. <i>European Neuropsychopharmacology</i> , 2021, 49, 38-39. | 0.3 | 0 |
| 17 | Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8623. | 1.8 | 20 |
| 18 | Multiple Comorbidity Profile of Psychiatric Disorders in Epilepsy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4104. | 1.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 704330. | 1.3 | 19 |
| 20 | Dysphoria and Irritabilityâ€”Diagnostic Pitfalls in the Assessment of Interictal Dysphoric Disorder in Epilepsy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4624. | 1.0 | 4 |
| 21 | Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases. <i>Frontiers in Psychiatry</i> , 2021, 12, 705190. | 1.3 | 1 |
| 22 | Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. <i>Medical Hypotheses</i> , 2020, 144, 110268. | 0.8 | 14 |
| 23 | <p>Ketamine in Bipolar Disorder: A Review</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2707-2717. | 1.0 | 22 |
| 24 | <p>Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2539-2551. | 1.0 | 10 |
| 25 | The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit â€” a clinical review. <i>Sleep Medicine</i> , 2020, 69, 127-134. | 0.8 | 32 |
| 26 | Psychological Functioning of Patients Undergoing Oral Surgery Procedures during the Regime Related with SARS-CoV-2 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 3344. | 1.0 | 15 |
| 27 | Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression. <i>Brain Sciences</i> , 2020, 10, 971. | 1.1 | 5 |
| 28 | Ketogenic Diet: A Dietary Modification as an Anxiolytic Approach?. <i>Nutrients</i> , 2020, 12, 3822. | 1.7 | 10 |
| 29 | Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review. <i>Frontiers in Psychiatry</i> , 2020, 11, 516. | 1.3 | 5 |
| 30 | Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. <i>Medicina (Lithuania)</i> , 2020, 56, 67. | 0.8 | 17 |
| 31 | The role of eugeroics in the treatment of affective disorders. <i>Psychiatria Polska</i> , 2020, 54, 21-33. | 0.2 | 1 |
| 32 | Clinical considerations of sleep related amnesic behaviours associated with zolpidem. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2020, 36, 23-31. | 0.1 | 0 |
| 33 | Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports. <i>Frontiers in Psychiatry</i> , 2019, 10, 520. | 1.3 | 12 |
| 34 | <p>Heart rate variability and incidence of depression during the first six months following first myocardial infarction</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1951-1956. | 1.0 | 8 |
| 35 | Expert advice on the management of valproate in women with bipolar disorder at childbearing age. <i>European Neuropsychopharmacology</i> , 2019, 29, 1199-1212. | 0.3 | 16 |
| 36 | Diagnosis of psychiatric comorbidities in epilepsy â€” The role of screening tools. <i>Epilepsy and Behavior</i> , 2019, 101, 106266. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | <p>Clozapine As Transformative Treatment In Bipolar Patients</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2901-2905. | 1.0 | 11 |
| 38 | Mechanisms of action of the ketogenic diet in depression. Neuroscience and Biobehavioral Reviews, 2019, 107, 422-423. | 2.9 | 8 |
| 39 | Psychometric properties and diagnostic utility of the Stateâ€™Trait Anxiety Inventory in epilepsy with and without comorbid anxiety disorder. Epilepsy and Behavior, 2019, 92, 221-225. | 0.9 | 20 |
| 40 | Blood-brain barrier permeability and physical exercise. Journal of Neuroinflammation, 2019, 16, 15. | 3.1 | 148 |
| 41 | Interictal dysphoric disorder of epilepsy: A continuing diagnostic challenge. Epilepsy and Behavior, 2019, 95, 34-38. | 0.9 | 13 |
| 42 | The Influence of Antidepressants on the Immune System. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 143-151. | 1.0 | 70 |
| 43 | Psychometric properties of the Polish version of the Hamilton Anxiety Rating Scale in patients with epilepsy with and without comorbid anxiety disorder. Epilepsy and Behavior, 2019, 94, 9-13. | 0.9 | 5 |
| 44 | Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II. Scientific Reports, 2019, 9, 5869. | 1.6 | 20 |
| 45 | Recommendations of the Polish Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatria Polska, 2019, 53, 263-276. | 0.2 | 7 |
| 46 | Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part III: Approach to pregnancy loss and unsuccessful in vitro treatment of infertility.. Psychiatria Polska, 2019, 53, 277-292. | 0.2 | 4 |
| 47 | Antipsychotic drugs in epilepsy. Neurologia I Neurochirurgia Polska, 2019, 53, 408-412. | 0.6 | 15 |
| 48 | Cardiovascular and metabolic side effects of second-generation antipsychotics - narrative review. European Journal of Translational and Clinical Medicine, 2019, 2, 70-77. | 0.0 | 0 |
| 49 | Neuropsychiatric presentation of SjÃ¶rgren syndrome. Polish Archives of Internal Medicine, 2019, 130, 68-69. | 0.3 | 1 |
| 50 | Role of copper and ketamine in major depressive disorder - an update. Psychiatria Danubina, 2019, 31, 520-523. | 0.2 | 1 |
| 51 | Efficacy of Ketamine in bipolar depression: focus on anhedonia. Psychiatria Danubina, 2019, 31, 554-560. | 0.2 | 12 |
| 52 | Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatria Danubina, 2019, 31, 585-590. | 0.2 | 14 |
| 53 | The neurobiology of addiction. A vulnerability/resilience perspective. European Journal of Psychiatry, 2018, 32, 139-148. | 0.7 | 7 |
| 54 | Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature. Journal of Psychoactive Drugs, 2018, 50, 275-280. | 1.0 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Letter to Editor regarding "Characterizing and predicting rates of delirium across general hospital settings". General Hospital Psychiatry, 2018, 53, 80-81. | 1.2 | 0 |
| 56 | 17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S27-S27. | 2.3 | 3 |
| 57 | Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 2018, 175, 225-231. | 4.0 | 441 |
| 58 | Prevalence of anxiety disorders in epilepsy. Epilepsy and Behavior, 2018, 79, 1-3. | 0.9 | 29 |
| 59 | Ketamine and magnesium common pathway of antidepressant action. Magnesium Research, 2018, 31, 33-38. | 0.4 | 4 |
| 60 | Depression among patients with epilepsy " A diagnostic approach. Epilepsy and Behavior, 2018, 88, 396. | 0.9 | 0 |
| 61 | Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment. Medical Hypotheses, 2018, 118, 74-77. | 0.8 | 21 |
| 62 | What really is a "gold standard" in depression recognition among patients with epilepsy?. Epilepsy and Behavior, 2018, 87, 249. | 0.9 | 2 |
| 63 | Validation of the Polish version of the Hospital Anxiety and Depression Scale for anxiety disorders in patients with epilepsy. Epilepsy and Behavior, 2018, 84, 162-165. | 0.9 | 18 |
| 64 | Role of copper in depression. Relationship with ketamine treatment. Medical Hypotheses, 2018, 119, 14-17. | 0.8 | 20 |
| 65 | Antidepressants in epilepsy. Neurologia I Neurochirurgia Polska, 2018, 52, 657-661. | 0.6 | 19 |
| 66 | Impulsivity in drug-naïve panic disorder. European Journal of Psychiatry, 2017, 31, 45-49. | 0.7 | 0 |
| 67 | Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy. Epilepsy and Behavior, 2017, 77, 58-61. | 0.9 | 12 |
| 68 | Therapeutic drug monitoring of atypical antipsychotics.. Psychiatria Polska, 2017, 51, 1059-1077. | 0.2 | 26 |
| 69 | A retrospective study of DRESS " drug reaction with eosinophilia and systemic symptoms. Psychiatria Polska, 2017, 51, 1079-1093. | 0.2 | 9 |
| 70 | Zinc, C-reactive protein, and cortisol in major depressive disorder: an exploratory analysis. Trace Elements and Electrolytes, 2017, 34, 104-106. | 0.1 | 1 |
| 71 | No relationship between baseline salivary alpha-amylase and State-Trait Anxiety Inventory Score in drug-naïve patients with short-illness-duration first episode major depressive disorder: An exploratory study. Journal of Clinical and Experimental Dentistry, 2017, 9, 0-0. | 0.5 | 2 |
| 72 | Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. Psychiatria Danubina, 2017, 29, 345-348. | 0.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Cortisol awakening response in drug-naïve panic disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1581-1585. | 1.0 | 0 |
| 74 | Magnesium, C-reactive protein, and cortisol in drug-naïve patients with short illness-duration, first episode major depressive disorder: possible immunomodulatory role for magnesium. <i>Magnesium Research</i> , 2016, 29, 169-174. | 0.4 | 10 |
| 75 | Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2016, 58, 97-101. | 0.9 | 24 |
| 76 | Validation of the Polish Version of the Hamilton Rating Scale for Depression in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2016, 62, 81-84. | 0.9 | 7 |
| 77 | Prevalence of self-reported insomnia in general population of Poland. <i>Psychiatria Polska</i> , 2016, 50, 165-173. | 0.2 | 62 |
| 78 | Reevaluating the prevalence and diagnostic subtypes of depressive disorders in epilepsy. <i>Epilepsy and Behavior</i> , 2015, 53, 15-19. | 0.9 | 14 |
| 79 | World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7. | 1.2 | 23 |
| 80 | An overview of interventions in drug-induced weight gain during clozapine treatment. <i>Psychiatria I Psychologia Kliniczna</i> , 2015, 15, 76-80. | 0.3 | 0 |
| 81 | The use of antiepileptic drugs in the prevention of clozapine-induced seizures. Literature review. <i>Psychiatria I Psychologia Kliniczna</i> , 2015, 15, 71-75. | 0.3 | 0 |
| 82 | Overlapping phenomena of bipolar disorder and epilepsy—a common pharmacological pathway. <i>Psychiatria Danubina</i> , 2015, 27 Suppl 1, S177-81. | 0.2 | 3 |
| 83 | Cortisol as an indicator of hypothalamic-pituitary-adrenal axis dysregulation in patients with panic disorder: a literature review. <i>Psychiatria Danubina</i> , 2015, 27 Suppl 1, S445-51. | 0.2 | 4 |
| 84 | Sleep Related Amnestic Behaviors due to Zolpidem. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 188-194. | 0.9 | 5 |
| 85 | Severe skin complications in patients treated with antidepressants: a literature review. <i>Postepy Dermatologii I Alergologii</i> , 2014, 2, 92-97. | 0.4 | 22 |
| 86 | C-reactive protein and cortisol in drug-naïve patients with short-illness-duration first episode major depressive disorder: Possible role of cortisol immunomodulatory action at early stage of the disease. <i>Journal of Affective Disorders</i> , 2014, 152-154, 534-537. | 2.0 | 34 |
| 87 | Low baseline salivary 3-methoxy-4-hydroxyphenylglycol (MHPG) in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 161, 4-7. | 2.0 | 3 |
| 88 | Prolactin response to buspirone is not impaired in drug-naïve first episode patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 152-154, 468-473. | 2.0 | 1 |
| 89 | Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature. <i>Journal of Substance Use</i> , 2014, 19, 388-393. | 0.3 | 12 |
| 90 | Low baseline salivary alpha-amylase in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 157, 14-17. | 2.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Zinc in drug-naïve patients with short-illness-duration first episode major depressive disorder: impact on psychopathological features. <i>Neuroendocrinology Letters</i> , 2014, 35, 741-5. | 0.2 | 1 |
| 92 | Salivary 5-hydroxyindole acetic acid (5-HIAA) in drug-naïve patients with short-illness-duration first episode major depressive disorder. <i>Neuroendocrinology Letters</i> , 2014, 35, 746-9. | 0.2 | 0 |
| 93 | Magnesium in drug-naïve patients with a short-duration, first episode of major depressive disorder: impact on psychopathological features. <i>Magnesium Research</i> , 2013, 26, 192-198. | 0.4 | 4 |
| 94 | Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84. | 1.2 | 327 |
| 95 | A cry for help, do not omit the signs. Dermatitis artefacta – psychiatric problems in dermatological diseases (a review of 5 cases). <i>Medical Science Monitor</i> , 2012, 18, CS85-CS89. | 0.5 | 10 |
| 96 | Mood disorders in epilepsy - diagnostic and methodological considerations. <i>Psychiatria Danubina</i> , 2012, 24 Suppl 1, S44-50. | 0.2 | 1 |
| 97 | Dermatitis artefacta—a long way from the first clinical symptoms to diagnosis. <i>Psychiatria Danubina</i> , 2011, 23, 73-5. | 0.2 | 7 |
| 98 | Promazine in the treatment of delusional parasitosis. <i>Psychiatria Danubina</i> , 2011, 23, 198-9. | 0.2 | 5 |
| 99 | Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 955-955. | 0.8 | 20 |
| 100 | Psychogenic axial myoclonus: report on two cases. <i>Neurological Sciences</i> , 2010, 31, 219-222. | 0.9 | 5 |
| 101 | Neurosyphilis presenting with depressive symptomatology: is it unusual?. <i>Acta Neuropsychiatrica</i> , 2008, 20, 110-110. | 1.0 | 3 |
| 102 | Dependence on zolpidem: Is pharmacokinetics important?. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 127-127. | 1.0 | 3 |
| 103 | Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 444-445. | 1.1 | 27 |
| 104 | Seizure following sudden zolpidem withdrawal. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 539-540. | 2.5 | 67 |
| 105 | Refractory schizophrenia treated with clozapine combined with zuclopenthixol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 781-783. | 2.5 | 2 |
| 106 | Factores asociados con la depresión en la enfermedad de Parkinson: un estudio transversal en una población polaca. <i>European Psychiatry (Ed Española)</i> , 2007, 14, 129-134. | 0.0 | 0 |
| 107 | Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. <i>European Psychiatry</i> , 2006, 21, 516-520. | 0.1 | 47 |
| 108 | Wilson's disease associated with delusional disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 758-760. | 1.0 | 28 |